MYCN and neuroblastoma: At present, the research and development of targeted drugs for MYCN primarily has the following ideas: (1) Prevent the abnormal expression of MYCN: For example, JQ1, a small-molecule inhibitor of the bromodomain and the extraterminal domain (BET) protein, can effectively down-regulate MYCN gene transcription and inhibit the proliferation of MYCN-amplified NB cells [212].